1932

Abstract

Following a major shortage of 99Mo in the 2009–2010 period, concern grew that the aging reactor production facilities needed to be replaced. Most producers were using highly enriched 235U (HEU) as the target material. The Organisation for Economic Co-operation and Development and the International Atomic Energy Agency sought to remedy these issues by removing HEU from medical isotope production and implementing full cost recovery to enable new production entities to compete with the existing multipurpose reactor facilities, which were heavily subsidized by their respective governments. This review examines the various approaches to producing 99Mo and/or 99mTc with a critical eye toward their potential success in () producing the medical isotopes and () being able to successfully enter and compete in the market. Because many of the new approaches are adapting existing technologies for commercial businesses, some of the details are of a proprietary nature and not available for in-depth technical review.

Keyword(s): 99Mo99mTcacceleratorHEULEUreactor
Loading

Article metrics loading...

/content/journals/10.1146/annurev-nucl-032020-021829
2020-10-19
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/nucl/70/1/annurev-nucl-032020-021829.html?itemId=/content/journals/10.1146/annurev-nucl-032020-021829&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Anger H. Biology and medicine quarterly report Rep., Univ. Calif. Radiat. Lab Berkeley: 1957.)
  2. 2. 
    Gasparini A. Celebrating the 60th anniversary of technetium-99m. Press Release, Oct. 24 https://www.bnl.gov/newsroom/news.php?a=213162 2018.)
  3. 3. 
    Eckelman WC. JACC Cardiovasc. Imaging 2:364 2009.)
  4. 4. 
    Beller GA, Watson DD. Semin. Nucl. Med. 21:173 1991.)
  5. 5. 
    Billinghurst MW, Hreczuch FW. J. Nucl. Med. 17:840 1976.)
  6. 6. 
    Lee S-K, Beyer GJ, Lee JS Nucl. Eng. Technol. 48:613 2016.)
  7. 7. 
    Natl. Acad. Sci. Eng. Med Molybdenum-99 for Medical Imaging Washington, DC: Natl. Acad. Press https://doi.org/10.17226/23563 2016.)
    [Crossref]
  8. 8. 
    NRC (Natl. Res. Counc.) Medical Isotope Production Without Highly Enriched Uranium Washington, DC: Natl. Acad 2009.)
  9. 9. 
    NRC (Natl. Res. Counc.) Molybdenum-99 for Medical Imaging Washington, DC: Natl. Acad 2016.)
  10. 10. 
    Paterson A, Druce M, Killen E J. Radioanal. Nucl. Chem. 305:13 2015.)
  11. 11. 
    Charlton K. Medical isotope supply review: 99Mo/99mTc market demand and production capacity projection 2018–2023 Paper presented at the 2018 NNSA Mo-99 Topical Meeting, Knoxville TN, Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S5-P2.pdf 2018.)
  12. 12. 
    Karcz P. NNSA's Mo-99 program: accelerating reliable, non-HEU Mo-99 production capabilities in the United States Paper presented at the 2019 NNSA Mo-99 Stakeholders Meeting Chicago, IL: Sep. 12. https://mo99.ne.anl.gov/2019stakeholders/pdfs/1.1_Karcz.pdf 2019.)
  13. 13. 
    Wagner C. Eden Radioisotopes Paper presented at the 2019 NNSA Mo-99 Stakeholders Meeting Chicago, IL: Sep. 12. https://mo99.ne.anl.gov/2019stakeholders/pdfs/3.1_Wagner.pdf 2019.)
  14. 14. 
    Bigles C. Coquí Pharma Paper presented at the 2018 NNSA Mo-99 Topical Meeting, Knoxville TN, Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S3-P3.pdf 2018.)
  15. 15. 
    Murphy H. BWX Technologies, Inc Paper presented at the 2019 NNSA Mo-99 Stakeholders Meeting Chicago, IL: Sep 12 2019.)
  16. 16. 
    Government of Canada Government of Canada Response to the Report of the Expert Review Panel on Medical Isotope Production Ottawa, Can: Gov. Can https://www.nrcan.gc.ca/sites/www.nrcan.gc.ca/files/energy/pdf/eneene/sources/uranuc/pdf/isotopes-gc-re-eng.pdf 2010.)
  17. 17. 
    Gillis C US nuclear medicine suppliers welcome HEU export ban delay. American Shipper Jan. 20. https://www.freightwaves.com/news/us-nuclear-medicine-suppliers-welcome-heu-export-ban-delay 2020.)
    [Google Scholar]
  18. 18. 
    Harvey J. NorthStar: The new producer and distributor of Mo-99 Paper presented at the 2019 NNSA Mo-99 Stakeholders Meeting Chicago, IL: Sep. 12. https://mo99.ne.anl.gov/2019stakeholders/pdfs/2.3_Harvey.pdf 2019.)
  19. 19. 
    Toth JJ et al. Production of molybdenum-99 using neutron capture methods Rep. PNNL-19895, RPT-59331-01 Rev 0, Pac. Northwest Natl. Lab Richland, WA: https://www.osti.gov/servlets/purl/1004126 2011.)
  20. 20. 
    De Jong M. Canadian Isotope Innovations Presentation to the Committee on State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium Ottawa: Can., Dec 16 2015.)
  21. 21. 
    Ross C et al. Phys. Can. 66:19 2010.)
  22. 22. 
    Fong A, Meyer TI, Zala K Making medical isotopes: report of the Task Force on Alternatives for Medical Isotope Production Rep., TRIUMF, Vancouver, Can 2008.)
  23. 23. 
    Chemerisov S. Accelerator based production of Mo-99: photonuclear approach Paper presented at the 2018 NNSA Mo-99 Topical Meeting Knoxville, TN: Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S11-P2.pdf 2018.)
  24. 24. 
    Pitas K. Next generation Mo-99 Paper presented at the 2018 NNSA Mo-99 Topical Meeting Knoxville, TN: Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S3-P2.pdf 2018.)
  25. 25. 
    Grimm T. Niowave's domestic production of Mo-99 and other fission fragments from LEU without a nuclear reactor Paper presented at the 2019 NNSA Mo-99 Stakeholders Meeting Chicago, IL: Sep. 12. https://mo99.ne.anl.gov/2019stakeholders/pdfs/2.4_Grimm.pdf 2019.)
  26. 26. 
    Gagnon K et al. Nucl. Med. Biol. 38:907 2011.)
  27. 27. 
    Bénard F et al. J. Nucl. Med. 55:1017 2014.)
  28. 28. 
    Schaffer P et al. Phys. Procedia 66:383 2015.)
  29. 29. 
    Andersson JD et al. Nucl. Med. Biol. 60:63 2018.)
  30. 30. 
    Guerin B. Project for producing Tc-99m for medical use, ACSI/CHUS/University of Alberta Consortium: state of molybdenum-99 production and utilization and progress toward eliminating use of highly enriched uranium Presentation to the Committee on State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium Ottawa, Can: Dec 16 2015.)
  31. 31. 
    Beaver JE, Hupf HB. J. Nucl. Med. 12:739 1971.)
  32. 32. 
    Saunders C. Prairie Isotope Production Enterprise: production of Mo-99 and Tc-99m: a secure and sustainable supply in Canada by 2016 Presentation to the Committee on State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium Ottawa, Can: Dec 16 2015.)
  33. 33. 
    Hou X et al. Phys. Med. Biol. 61:542 2016.)
  34. 34. 
    Kumlin J et al. Updates on implementation of cyclotron-produced Tc-99m Paper presented at the 2018 NNSA Mo-99 Topical Meeting Knoxville, TN: Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S7-P3.pdf 2018.)
  35. 35. 
    Alliance Medical ARTMS Products Inc. partners with Alliance Medical to modernize, stabilize UK medical isotope supply chain. Press Release, May 16. https://www.alliancemedical.co.uk/news/artms-products-inc-partners-with-alliance-medical-to-modernize-stabilize-uk-medical-isotope 2017.)
  36. 36. 
    IAEA (Int. At. Energy Agency) Cyclotron based production of technetium-99m IAEA Radioisot. Radiopharm. Rep. 2, IAEA Vienna: 2017.)
  37. 37. 
    Haas C. Northwest Medical Isotopes, LLC radioisotope production facility overview Paper presented at the 2018 NNSA Mo-99 Topical Meeting Knoxville, TN: Sep 23–27 https://mo99.ne.anl.gov/2018/pdfs/presentations/S3-P4.pdf 2018.)
  38. 38. 
    Thro PY et al. European research reactor position paper by CEA, NCBJ, NRG, PALLAS, RCR, SCK·CEN and TUM Position Pap., Eur. Comm Brussels: https://ec.europa.eu/euratom/docs/European%20Research%20Reactor%20Position%20Paper%20for%20DGE%20Energy%20%202018%20report_20180801.pdf 2018.)
  39. 39. 
    Natl. Acad. Sci. Eng. Med Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets: Proceedings of a Symposium Washington, DC: Natl. Acad 2018.)
  40. 40. 
    Eur. Pharmacop. Comm Sodium pertechnetate (99mTc) injection (cyclotron-produced) Monogr. 2891, EDQM Counc. Eur Strasbourg, Fr: 2016.)
  41. 41. 
    OECD NEA (Organ. Econ. Co-op. Dev. Nucl. Energy Agency) Joint declaration on the security of supply of medical radioisotopes Jt. Declar., OECD, Paris, Fr 2015.)
/content/journals/10.1146/annurev-nucl-032020-021829
Loading
/content/journals/10.1146/annurev-nucl-032020-021829
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error